Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes

被引:73
作者
Home, P [1 ]
机构
[1] Newcastle Univ, Sch Med, Sch Clin Med Sci Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
blood glucose; diabetes complications; diabetes mellitus; glucose tolerance test; hyperglycaemia; nateglinide; post-prandial glucose control;
D O I
10.1185/030079905X49662
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: People with Type 2 diabetes mellitus are at high risk of cardiovascular disease and microvascular complications. A number of epidemiological studies have shown a strong relationship between the prevalence of vascular complications and raised levels of plasma glucose and glycated haemoglobin (HbA(1c)). Accumulating evidence supports the superior independent prognostic importance of the post-challenge glucose level, measured either 1 or 2 h after a glucose load. Thus, data from studies conducted in Europe, the USA, and particularly the Pacific rim and South Asia suggest that 2-h glucose is a better predictor of cardiovascular and all-cause mortality than pre-breakfast glucose, both in people with diabetes and those with pre-diabetic impaired glucose tolerance (IGT). Pathophysiological studies suggest that postprandial rises in hyperglycaemia can trigger endothelial damage through multiple mechanisms, including increased oxidative stress and the increased expression of atherogenic circulating adhesion molecules and inflammatory cytokines that induce and regulate cell recruitment, migration, growth, and proliferation. Optimal pharmacological control of meal-time glucose levels can help to lower the HbA(1c) and thus may reduce the incidence of vascular complications in many people with diabetes. Moreover, emerging evidence suggests that reducing meal-time hyperglycaemia may delay the progression from pre-diabetic states toward overt diabetes. Scope: This review (based on MEDLINE searches, 1980-2005) examines the evidence linking the microvascular and macrovascular complications of diabetes and glycaemic control, assesses the relative contributions of basal and meal-time concentrations, and considers the implications for optimal treatment for people with Type 2 diabetes or with prediabetic IGT.
引用
收藏
页码:989 / 998
页数:10
相关论文
共 82 条
[71]   Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level [J].
Temelkova-Kurktschiev, TS ;
Koehler, C ;
Henkel, E ;
Leonhardt, W ;
Fuecker, K ;
Hanefeld, M .
DIABETES CARE, 2000, 23 (12) :1830-1834
[72]   Association of postprandial hypertriglyceridemia and carotid intima/media thickness in patients with type 2 diabetes [J].
Teno, S ;
Uto, Y ;
Nagashima, H ;
Endoh, Y ;
Iwamoto, Y ;
Omori, Y ;
Takizawa, T .
DIABETES CARE, 2000, 23 (09) :1401-1406
[73]   Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus [J].
Tentolouris, N ;
Kolia, M ;
Tselepis, AD ;
Perea, D ;
Kitsou, E ;
Kyriaki, D ;
Tambaki, AP ;
Karabina, SP ;
Sala, C ;
Fragoulopoulos, E ;
Katsilambros, N .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2003, 111 (06) :370-373
[74]   Impaired glucose tolerance is a risk factor per cardiovascular disease, but not impaired fasting glucose - The Funagata diabetes study [J].
Tominaga, M ;
Eguchi, H ;
Manaka, H ;
Igarashi, K ;
Kato, T ;
Sekikawa, A .
DIABETES CARE, 1999, 22 (06) :920-924
[75]  
TURNER RC, 1991, DIABETOLOGIA, V34, P877
[76]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
[77]   Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: Assessment using nateglinide, a new insulin secretagogue [J].
Uchino, H ;
Niwa, M ;
Shimizu, T ;
Nishiyama, K ;
Kawamori, R .
ENDOCRINE JOURNAL, 2000, 47 (05) :639-641
[78]   Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes [J].
Vakkilainen, J ;
Mero, N ;
Schweizer, A ;
Foley, JE ;
Taskinen, MR .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (06) :484-490
[79]   α-Glucosidase inhibitors for patients with type 2 diabetes -: Results from a cochrane systematic review and meta-analysis [J].
van de Laar, FA ;
Lucassen, PL ;
Akkermans, RP ;
van de Lisdonk, FH ;
Rutten, GE ;
van Weel, C .
DIABETES CARE, 2005, 28 (01) :154-163
[80]  
Wilson P W, 1985, Monogr Atheroscler, V13, P1